Jinhe Biotechnology (China) Today
| 002688 Stock | 4.26 0.07 1.62% |
Performance11 of 100
| Odds Of DistressLess than 50
|
Jinhe Biotechnology is trading at 4.26 as of the 19th of November 2024, a 1.62 percent decrease since the beginning of the trading day. The stock's open price was 4.33. Jinhe Biotechnology has 50 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. Equity ratings for Jinhe Biotechnology Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of August 2024 and ending today, the 19th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of July 2012 | Category Healthcare | Classification Health Care |
Jinhe Biotechnology is entity of China. It is traded as Stock on SHE exchange. The company has 771.69 M outstanding shares. More on Jinhe Biotechnology Co
Moving together with Jinhe Stock
Follow Valuation Profit Patterns Daily Balance Of Power
Check how we calculate scores
Jinhe Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Jinhe Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Jinhe Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | Biotech (View all Themes) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Biotech, Health Care, Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
Jinhe Biotechnology's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Jinhe Biotechnology's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsJinhe Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Jinhe Biotechnology's financial leverage. It provides some insight into what part of Jinhe Biotechnology's total assets is financed by creditors.
| |||||
Jinhe Biotechnology Co (002688) is traded on Shenzhen Stock Exchange in China and employs 2,316 people. Jinhe Biotechnology is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Jinhe Biotechnology's market, we take the total number of its shares issued and multiply it by Jinhe Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Jinhe Biotechnology operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 771.69 M outstanding shares.
Jinhe Biotechnology generates positive cash flow from operations, but has no cash available
Check Jinhe Biotechnology Probability Of Bankruptcy
Ownership AllocationJinhe Biotechnology Co has a total of 771.69 Million outstanding shares. Jinhe Biotechnology secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Jinhe Ownership Details
Jinhe Biotechnology Risk Profiles
Although Jinhe Biotechnology's alpha and beta are two of the key measurements used to evaluate Jinhe Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.6 | |||
| Semi Deviation | 1.73 | |||
| Standard Deviation | 2.13 | |||
| Variance | 4.55 |
Jinhe Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Jinhe Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Jinhe Biotechnology Corporate Directors
| Zhi Wang | Deputy Director | Profile | |
| Changxian Xie | GM Director | Profile | |
| Manman Lu | Board Director | Profile | |
| Yueqing Wang | Deputy Director | Profile |
Other Information on Investing in Jinhe Stock
Jinhe Biotechnology financial ratios help investors to determine whether Jinhe Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jinhe with respect to the benefits of owning Jinhe Biotechnology security.